Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCirata Regulatory News (CRTA)

Share Price Information for Cirata (CRTA)

Share Price is delayed by 15 minutes
Get Live Data
17.50    0.00 (0.00%)
Bid:
17.00
Ask:
17.95
Spread: 0.95 (5.588%)
Market Cap: £22.12m
CRTA Live PriceLast checked at - London Stock Exchange

Intraday Cirata Share Chart

PrimaryBid Offer

16 Jul 2024 16:47

RNS Number : 6461W
Cirata PLC
16 July 2024
Β 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 (WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR").

THIS ANNOUNCEMENT IS FOR INFORMATIONAL PURPOSES ONLY, AND DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO SELL OR ISSUE, OR ANY SOLICITATION OF AN OFFER TO PURCHASE OR SUBSCRIBE FOR, ANY SECURITIES OF CIRATA PLC.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT IN, ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT.

THIS ANNOUNCEMENT AMOUNTS TO A FINANCIAL PROMOTION FOR THE PURPOSES OF SECTION 21 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 ("FSMA") AND HAS BEEN APPROVED BY PRIMARYBID LIMITED WHICH IS AUTHORISED AND REGULATED BY THE FINANCIAL CONDUCT AUTHORITY (FRNΒ 779021).

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, CANADA OR JAPAN.

Β 

16 July 2024

Β 

Cirata Plc

("Cirata" or the "Company")

PrimaryBid Offer

● Cirata Plc announces an offer for subscription of new Ordinary Shares via PrimaryBid;

● The Issue Price for the new Ordinary Shares is 55 pence per new Ordinary Share, representing a discount of 5.2 per cent to the closing mid-price of the Company's existing Ordinary Shares on 15 July 2024;

● Investors can take part through PrimaryBid's extensive network of retail brokers, wealth managers and investment platforms, (subject to such partners' participation);

● The PrimaryBid Offer is available to both existing shareholders and new investors;

● The new Ordinary Shares to be issued pursuant to the PrimaryBid Offer and the Placing will be sold at the Issue Price;

● There is a minimum subscription of Β£250 per investor in the PrimaryBid Offer;

● No commission will be charged by PrimaryBid on applications to the PrimaryBid Offer.

PrimaryBid Offer

Cirata plc (LSE: CRTA), the data activation platform companyΒ quoted on AIM, is pleased to announce,Β an offer for subscription of new ordinary shares of 10 pence each in the capital of the Company ("Ordinary Shares")Β via PrimaryBid (the "PrimaryBid Offer") at an issue price of 55 pence per new Ordinary Share (the "Issue Price"), being a discount of 5.2 per cent to the closing mid-price of the Company's existing Ordinary Shares on 15 July 2024 (the "Retail Shares"). The Company is also conducting a placing of new Ordinary Shares at the Issue Price by way of an accelerated bookbuilding process (the "Placing"), a direct subscription for new Ordinary Shares by certain third party investors (the "Direct Subscription") and a subscription for new Ordinary Shares by certain Directors and members of management (the "Management Subscription" and together with the Direct Subscription, the "Subscription") as announced earlier today.

The PrimaryBid Offer is conditional on the new Ordinary Shares to be issued pursuant to the PrimaryBid Offer, the Subscription and the Placing being admitted to trading on AIM ("Admission").Β Admission is expected to take place at 8.00 a.m. on 22 July 2024. The PrimaryBid Offer will not be completed without the Placing also being completed.

The Company will use the funds raised to:

Β· take the business through to cash flow breakeven, which the Company aspires to get to as the Company exits FY24;

Β· give all stakeholders (including customers) confidence; and

Β· allow the business to capitalise on its full potential.

The Retail Shares will, when issued, be credited as fully paid and will rank pari passu in all respects with existing Ordinary Shares including the right to receive all dividends and other distributions declared, made or paid after their date of issue.

Reason for the PrimaryBid Offer

While the Placing and the Subscription have been structured as a non-pre-emptive offer within the Company's existing authorities from shareholders so as to minimise cost and time to completion, the Company values its retail investor base and is therefore pleased to provide retail investors with the opportunity to participate in the PrimaryBid Offer.Β 

Existing shareholders and new investors can access the PrimaryBid Offer through PrimaryBid's extensive partner network of investment platforms, retail brokers and wealth managers, subject to such partners' participation. A list of PrimaryBid's distribution partners can be found here.

Some partners may only accept applications from existing shareholders and/or existing customers.

After consideration of the various options available to it, the Company believes that the separate PrimaryBid Offer is in the best interests of shareholders, as well as wider stakeholders in the Company.

The PrimaryBid Offer will open to investors resident and physically located in the United Kingdom following the release of this Announcement. The PrimaryBid Offer is expected to close at the same time as the Placing on 16 July 2024 and may close early if it is oversubscribed.

There is a minimum subscription amount of Β£250 per investor in the PrimaryBid Offer.

The Company reserves the right to scale back any order at its discretion. The Company and PrimaryBid reserve the right to reject any application for subscription under the PrimaryBid Offer without giving any reason for such rejection.

Investors wishing to apply for Retail Shares should contact their investment platform, retail broker or wealth manager for details of their terms and conditions, process (including for using their ISA, SIPP or GIA and the procedure for application and payment for Retail Shares and details regarding how any funds committed will be treated if the PrimaryBid Offer does not proceed) and any relevant fees or charges.

The Retail Shares to be issued pursuant to the PrimaryBid Offer will be issued free of all liens, charges and encumbrances and will, when issued and fully paid, rankΒ pari passuΒ in all respects with the new Ordinary Shares to be issued pursuant to the Placing and the Subscription, and the Company's existing Ordinary Shares.

Brokers wishing to offer their customers access to the PrimaryBid Offer and future PrimaryBid transactions, should contact partners@primarybid.com.

Enquiries

Cirata

Stephen Kelly, Chief Executive Officer

Ijoma Maluza, Chief Financial Officer

Daniel Hayes, Investor Relations

Β 

Β 

Β 

Via FTI Consulting

Β 

Β 

Β 

Β 

FTI Consulting

Matt Dixon / Kwaku Aning / Usama Ali

Β 

Β 

Β 

+44 (0)20 3727 1137

Β 

Β 

Β 

PrimaryBid

Nick Smith / James Deal

enquiries@primarybid.com

Β 

Important notices

The PrimaryBid Offer is offered under the exemptions from the need for a prospectus allowed under the FCA's Prospectus Regulation Rules. As such, there is no need for publication of aΒ prospectus pursuant to the Prospectus Regulation Rules, or for approval of the same by the Financial Conduct Authority (as competent authority under Regulation (EU) 2017/1129 as it forms part of retained EU law as defined in the European Union (Withdrawal) Act 2018).Β 

The PrimaryBid Offer is not being made into the United States, Australia, Canada, the Republic of South Africa, Japan or any other jurisdiction where it would be unlawful to do so.

This Announcement is not for publication or distribution, directly or indirectly, in or into the United States of America. This Announcement is not an offer of securities for sale into the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States, except pursuant to an applicable exemption from registration. No public offering of securities is being made in the United States.

This Announcement and the information contained herein, is restricted and is not for publication, release or distribution, directly or indirectly, in whole or in part, in or into Australia, Canada, the Republic of South Africa, Japan or any other jurisdiction in which such publication, release or distribution would be unlawful. Further, this Announcement is for information purposes only and is not an offer of securities in any jurisdiction.

Investors should make their own investigations into the merits of an investment in the Company. Nothing in this Announcement amounts to a recommendation to invest in the Company or amounts to investment, taxation or legal advice.

It should be noted that a subscription for new Ordinary Shares and investment in the Company carries a number of risks. Investors should contact their investment platform, retail broker or wealth manager for details of any relevant risk warnings. Investors should take independent advice from a person experienced in advising on investment in securities such as the new Ordinary Shares if they are in any doubt.Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Β 

IMPORTANT NOTICES

Β 

Details of the Company's board of directors and principal advisers and other information in respect of the Company can be found on the Company's website at https://cirata.com/investors/aim-rule-26.

The Directors of the Company shall not be participating in the PrimaryBid Offer.

Information regarding the Company's share capital, dividend policy, principal establishments, and material contracts, together with details of directors' existing interests and material debentures and loans to which the Company is party can be found in its most recent annual report and accounts, available at https://cirata.com/investors/reports-and-presentations or at https://cirata.com/investors/shareholders.Β 

No amounts are being written off or provided for as goodwill or preliminary expenses in connection with the funds raised as part of this offer. No benefit is being given to any promoter in connection with the funds raised as part of this offer.

A copy of this document has been delivered to the registrar of companies in accordance with Article 5 of the Companies (General Provisions) (Jersey) Order 2002, and he has given, and has not withdrawn, his consent to its circulation. The Jersey Financial Services Commission has given, and has not withdrawn, its consent under Article 2 of the Control of Borrowing (Jersey) Order 1958 to the issue of shares in the company. It must be distinctly understood that, in giving these consents, neither the registrar of companies nor the Jersey Financial Services Commission takes any responsibility for the financial soundness of the company or for the correctness of any statements made, or opinions expressed, with regard to it.

If you are in any doubt about the contents of this document you should consult your stockbroker, bank manager, solicitor, accountant or other financial adviser.

The directors of the Company have taken all reasonable care to ensure that the facts stated in this document are true and accurate in all material respects, and that there are no other facts the omission of which would make misleading any statement in the document, whether of facts or of opinion. All the directors accept responsibility accordingly.

The value of Ordinary Shares and the income from them is not guaranteed and can fall as well as rise due to stock market and currency movements. When you sell your investment, you may get back less than you originally invested. Figures refer to past performance and past performance is not a reliable indicator of future results. Returns may increase or decrease as a result of currency fluctuations.

Certain statements in this announcement are forward-looking statements which are based on the Company's expectations, intentions and projections regarding its future performance, anticipated events or trends and other matters that are not historical facts. These forward-looking statements, which may use words such as "aim", "anticipate", "believe", "intend", "estimate", "expect" and words of similar meaning, include all matters that are not historical facts. These forward-looking statements involve risks, assumptions and uncertainties that could cause the actual results of operations, financial condition, liquidity and dividend policy and the development of the industries in which the Company's businesses operate to differ materially from the impression created by the forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Given those risks and uncertainties, prospective investors are cautioned not to place undue reliance on forward-looking statements.

These forward-looking statements speak only as at the date of this announcement and cannot be relied upon as a guide to future performance. The Company expressly disclaims any obligation or undertaking to update or revise any forward-looking statements contained herein to reflect actual results or any change in the assumptions, conditions or circumstances on which any such statements are based unless required to do so by law, the AIM Rules or any appropriate regulatory authority.

The information in this announcement is for background purposes only and does not purport to be full or complete. Neither the Company nor any of its respective affiliates, accepts any responsibility or liability whatsoever for, or makes any representation or warranty, express or implied, as to this announcement, including the truth, accuracy or completeness of the information in this announcement (or whether any information has been omitted from the announcement) or any other information relating to the Company or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of the announcement or its contents or otherwise arising in connection therewith. The Company and its affiliates, accordingly disclaim any and all liability whether arising in tort, contract or otherwise which they might otherwise be found to have in respect of this announcement or its contents or otherwise arising in connection therewith.

Any indication in this announcement of the price at which the Ordinary Share have been bought or sold in the past cannot be relied upon as a guide to future performance. It should be remembered that the price of securities and the income from them can go down as well as up.

Β 

END

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
IOEBUGDRCXBDGSL
Date   Source Headline
1st Jun 20267:00 amRNSBlock Listing Return
20th May 20267:00 amRNSResult of AGM
5th May 20267:00 amRNSHolding(s) in Company
23rd Apr 20268:52 amRNSAmendment to Notice of Annual General Meeting
21st Apr 20267:00 amRNSGrant of Awards & PDMR Dealing
14th Apr 20267:00 amRNSTrading Statement
31st Mar 20263:39 pmRNSManagement Changes
31st Mar 20267:00 amRNSPreliminary Results
4th Feb 20268:54 amRNSGrant of Awards & PDMR Dealing
14th Jan 20267:00 amRNSQ4 FY25 Trading Update
19th Dec 20252:50 pmRNSDevOps Final Consideration Received
19th Dec 20252:50 pmRNSDevOps Final Consideration Received
1st Dec 20259:35 amRNSBlock Listing Return
27th Nov 20257:00 amRNSFinancial Conduct Authority Update
17th Nov 20257:00 amRNS$6.7m Multiyear Contract win
27th Oct 202510:05 amRNSNotification of Major Holdings
16th Oct 20257:00 amRNSTrading Statement
13th Oct 20257:00 amRNS$3.1m Multiyear Contract with leading US Insurer
12th Sep 202511:02 amRNSGrant of Awards & PDMR Dealing
10th Sep 20257:00 amRNSNotification of Major Holdings
9th Sep 20258:00 amRNS-RCirata launches new data platform
3rd Sep 20257:00 amRNSInterim results
13th Aug 20257:00 amRNSGrant of Share Options to PDMRs
11th Aug 20257:00 amRNSCompletion of DevOps Divestment
15th Jul 20257:07 amRNSQ2 and H1FY25 Trading Update
30th Jun 20257:01 amRNSHolding(s) in Company
30th Jun 20257:00 amRNS$700K Multiyear Data Integration Contract Renewal
10th Jun 20257:00 amRNSBoard Appointment
3rd Jun 20252:39 pmRNSBlock Listing Return
8th May 20254:47 pmRNSResult of AGM
29th Apr 202511:44 amRNSGrant of Share Options to PDMRs
16th Apr 20257:00 amRNSQ1FY25 Trading Statement
8th Apr 20257:00 amRNSAnnual Report & Notice of AGM
2nd Apr 20253:51 pmRNSNotification of Major Holdings
31st Mar 20257:01 amRNSContract win
31st Mar 20257:00 amRNSPreliminary Results
27th Feb 20257:00 amRNSNew logo in Telecom sector
20th Feb 20257:00 amRNSTotal Voting Rights
20th Jan 20256:29 pmRNSPDMR dealings and Total Voting Rights
9th Jan 20257:00 amRNSQ4FY24 Trading Update
16th Dec 20247:00 amRNSContract Win and FY24 Guidance
13th Dec 20243:46 pmRNSVesting of Restricted Stock & Director Dealings
11th Dec 20247:00 amRNSIssue of Equity
9th Dec 20247:00 amRNSMarvell Contract Renewal
2nd Dec 20243:40 pmRNSBlock Listing Return
1st Nov 20247:00 amRNSGrant of Share Options to PDMRs
24th Oct 20247:00 amRNSPDMR Transactions
9th Oct 20247:00 amRNSQ3 Trading Update and Outlook
2nd Oct 20243:19 pmRNSAmendment of OEM sales partnership with IBM
1st Oct 20247:00 amRNSBoard Appointments

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.